

# CONTENTS

<b>PREFACE</b>	<b>xxiii</b>
<b>CONTRIBUTORS</b>	<b>xxv</b>
<b>PART I INTRODUCTION</b>	<b>1</b>
<b>1 Fusion Proteins: Applications and Challenges</b>	<b>3</b>
<i>Stefan R. Schmidt</i>	
1.1 History, 3	
1.2 Definitions and Categories, 4	
1.3 Patenting, 5	
1.4 Design and Engineering, 6	
1.4.1 Orientation of Fusion Proteins, 6	
1.4.2 Linker Engineering, 7	
1.4.3 Oligomerization of Fusion Proteins, 8	
1.4.4 Immunogenicity, 9	
1.4.5 Mutagenesis for Molecule Optimization, 9	
1.5 Manufacturing, 10	
1.5.1 Upstream Process, 10	
1.5.2 Downstream Process, 12	
1.5.3 Formulation, 13	
1.5.4 Process Economies, 13	
1.5.5 Glycosylation, 14	
1.6 Regulatory Challenges, 15	
1.7 Competition and Market, 16	
1.8 Conclusion and Future Perspective, 17	
References, 18	
<b>2 Analyzing and Forecasting the Fusion Protein Market and Pipeline</b>	<b>25</b>
<i>Mark Belsey and Giles Somers</i>	
2.1 Introduction, 25	
2.2 Market Sales Dynamics of the FP Market, 25	

- 5.5.2 Correlation of Clinical Immunogenicity of Fusion Proteins with *In Silico* Risk Estimates, 83
- 5.6 Preclinical and Clinical Immunogenicity Assessment Strategy, 85
  - 5.6.1 Strategy and Recommendation, 85
- 5.7 Conclusions, 87
- Acknowledgment, 87
- References, 87

## **PART II THE TRIPLE T PARADIGM: TIME, TOXIN, TARGETING 91**

### **IIA TIME: FUSION PROTEIN STRATEGIES FOR HALF-LIFE EXTENSION 93**

#### **6 Fusion Proteins for Half-Life Extension 93**

*Stefan R. Schmidt*

- 6.1 Introduction, 93
- 6.2 Half-Life Extension Through Size and Recycling, 94
  - 6.2.1 Direct Genetic Fusions, 94
    - 6.2.1.1 Albumin Fusions, 94
    - 6.2.1.2 Fc Fusions, 97
    - 6.2.1.3 Transferrin Fusions, 99
  - 6.2.2 Half-Life Extension Through Attachment to Large Proteins, 99
- 6.3 Half-Life Extension Through Increase of Hydrodynamic Radius, 100
  - 6.3.1 Repetitive Peptide Fusions, 100
  - 6.3.2 Glycosylated Peptides, 101
- 6.4 Aggregate Forming Peptide Fusions, 102
- 6.5 Other Concepts, 103
- 6.6 Conclusions and Future Perspective, 103
- References, 104

#### **7 Monomeric Fc-Fusion Proteins 107**

*Baisong Mei, Susan C. Low, Snezana Krassova, Robert T. Peters, Glenn F. Pierce, and Jennifer A. Dumont*

- 7.1 Introduction, 107
- 7.2 FcRn and Monomeric Fc-Fusion Proteins, 108
  - 7.2.1 FcRn Expression and Function, 108
  - 7.2.2 FcRn for the Delivery of Fc-Fusion Proteins, 108
- 7.3 Typical Applications, 109
  - 7.3.1 Interferon Beta-Fc Monomer, 110
  - 7.3.2 Interferon  $\alpha$ -Fc Monomer, 110
  - 7.3.3 Factor VIII-Fc Monomer, 111
  - 7.3.4 Factor IX-Fc Monomer, 113
- 7.4 Alternative Applications, 114
  - 7.4.1 Follicle Stimulating Hormone-Fc-Fusion Proteins, 115
  - 7.4.2 Cytokine-Fc-Fusion Proteins, 115
- 7.5 Expression and Purification of Monomeric Fc-Fusion Proteins, 116
- 7.6 Conclusions and Future Perspectives, 118
- References, 118

#### **8 Peptide-Fc Fusion Therapeutics: Applications and Challenges 123**

*Chichi Huang and Ronald V. Swanson*

- 8.1 Introduction, 123

- 8.2 Peptide Drugs, 124
  - 8.2.1 The Limitations of Native Endogenous Peptides in Drug Development, 124
  - 8.2.2 Chemical Modification of Peptides to Reduce Proteolytic Degradation, 124
  - 8.2.3 Constraining Peptides to be More Resistant to Protease Cleavage, 125
  - 8.2.4 Peptide Therapeutics Play an Important Role in Drug Development, 125
  - 8.2.5 Most Peptide Drugs Act as Receptor Agonists, 125
- 8.3 Technologies Used for Reducing *In Vivo* Clearance of Therapeutic Peptides, 126
  - 8.3.1 PEGylation, 126
  - 8.3.2 Human Serum Albumin Fusions, 126
  - 8.3.3 Other Approaches, 127
- 8.4 Fc-Fusion Proteins in Drug Development, 127
  - 8.4.1 The Structure of Fc-Fusion Proteins, 127
  - 8.4.2 Fc-Fusion Therapeutics, 127
    - 8.4.2.1 Enbrel<sup>®</sup>, 128
    - 8.4.2.2 Amevive<sup>®</sup>, 128
    - 8.4.2.3 Orencia<sup>®</sup>, 129
    - 8.4.2.4 Arcalyst<sup>®</sup> (Also Known as IL-1 Trap or Rilonacept), 129
    - 8.4.2.5 Other Fc-Fusion Protein Therapeutics, 131
- 8.5 Peptide-Fc-Fusion Therapeutics, 131
  - 8.5.1 Peptibody, 131
    - 8.5.1.1 NPlate<sup>®</sup> (Romiplostim, AMG531), 131
    - 8.5.1.2 AMG 386 (2xCon4(C)), 131
    - 8.5.1.3 A-623 (AMG 623), 132
    - 8.5.1.4 Dulaglutide (LY2189265), 132
  - 8.5.2 Mimetibody<sup>™</sup> Technology, 133
    - 8.5.2.1 CNTO 528/CNTO 530, 133
    - 8.5.2.2 CNTO736, 133
- 8.6 Considerations and Challenges for Engineering Peptide-Fc-Fusion Therapeutics, 133
  - 8.6.1 Improving Activity, 134
  - 8.6.2 Improving Stability, 134
  - 8.6.3 Improving Pharmacokinetic Profile, 135
  - 8.6.4 Improving Solubility and Reducing Aggregation, 135
  - 8.6.5 Reducing Heterogeneity, 135
  - 8.6.6 Isotype Selection, 137
  - 8.6.7 Tailoring Fc-Effector Functions to Fit Individual Needs, 137
  - 8.6.8 Reducing Immunogenicity, 138
- 8.7 Conclusions, 138
- Acknowledgment, 138
- References, 138

## 9 Receptor-Fc and Ligand Traps as High-Affinity Biological Blockers: Development and Clinical Applications

143

*Aris N. Economides and Neil Stahl*

- 9.1 Introduction, 143
- 9.2 Etanercept as a Prototypical Receptor-Fc-Based Cytokine Blocker, 144
- 9.3 Heteromeric Traps for Ligands Utilizing Multicomponent Receptor Systems with Shared Subunits, 144

- 9.3.1 Proof-of-Concept for High-Affinity Traps for Ligands Utilizing Multicomponent Receptor Systems, 148
- 9.3.2 Turning Heterodimeric Soluble Receptor-Based Ligand Traps into Therapeutics, 150
- 9.4 Development and Clinical Application of an Interleukin 1 Trap: Rilonacept, 151
- 9.5 Development and Clinical Application of a VEGF Trap, 151
- 9.6 “To Trap Or Not To Trap?” Advantages and Disadvantages of Receptor-Fc Fusions and Traps Versus Antibodies, 152
  - 9.6.1 Multiple Ligand Binding, 152
  - 9.6.2 Signaling of Receptor-Fc Fusions, 154
  - 9.6.3 Immunogenicity, 155
- 9.7 Conclusion, 155
- Acknowledgment, 155
- References, 155

**10 Recombinant Albumin Fusion Proteins 163**

*Thomas Weimer, Hubert J. Metzner, and Stefan Schulte*

- 10.1 Concept, 163
- 10.2 Technological Aspects, 164
- 10.3 Typical Applications and Indications, 164
  - 10.3.1 Albumin Fusion Proteins in Late-Stage Development, 167
    - 10.3.1.1 Interferon- $\alpha$ , 167
    - 10.3.1.2 Glucagon-Like Peptide-1, 167
    - 10.3.1.3 Granulocyte Colony-Stimulating Factor, 168
  - 10.3.2 Albumin Fusion Proteins in Early-Stage Development, 168
    - 10.3.2.1 Interleukin-2, 168
    - 10.3.2.2 Insulin, 168
    - 10.3.2.3 Growth Hormone, 169
    - 10.3.2.4 Butyrylcholinesterase and Cocaine Hydrolase, 169
    - 10.3.2.5 B-Type Natriuretic Peptide, 169
    - 10.3.2.6 Erythropoietin, 170
    - 10.3.2.7 Barbourin, 170
    - 10.3.2.8 Hirudin, 170
    - 10.3.2.9 Factor VII, 170
    - 10.3.2.10 Factor IX, 171
    - 10.3.2.11 Infestin-4, 171
    - 10.3.2.12 Thioredoxin, 172
    - 10.3.2.13 Thymosin- $\alpha$ 1, 172
    - 10.3.2.14 Antibody Fragments, 172
- 10.4 Successes and Failures in Preclinical and Clinical Research, 172
  - 10.4.1 Interferon- $\alpha$ , 172
  - 10.4.2 FVII and FIX, 173
- 10.5 Challenges, 173
- 10.6 Future Perspectives, 174
- 10.7 Conclusion, 174
- Acknowledgment, 174
- References, 174

**11 Albumin-Binding Fusion Proteins in the Development of Novel Long-Acting Therapeutics 179**

*Adam Walker, Gráinne Dunlevy, and Peter Topley*

- 11.1 Introduction, 179
- 11.2 Clinically Validated Half-Life Extension Technologies—An Overview, 180

- 11.2.1 PEGylation, 180
- 11.2.2 Serum Albumin Fusion, 180
- 11.2.3 Anti-Serum Albumin Domain Antibodies in the Development of Novel Half-Life Extension Technologies, 181
- 11.3 Interferon- $\alpha$  Fused to Human Serum Albumin or AlbuDAb—A Direct Comparison of HSA and AlbuDAb Fusion Technologies, 182
  - 11.3.1 *In Vitro* Potency of HSA and AlbuDAb Fusion Proteins, 182
  - 11.3.2 Pharmacokinetics of HSA and AlbuDAb Fusion Proteins, 184
  - 11.3.3 *In Vivo* Efficacy of HSA and AlbuDAb Fusion Proteins, 185
- 11.4 Nanobodies in the Development of Alternative Half-Life Extension Technologies Based on Single Immunoglobulin Variable Domains, 186
- 11.5 Novel Half-Life Extension Technologies—Alternative Approaches to Single Immunoglobulin Variable Domains, 187
  - 11.5.1 Serum Albumin Binding Peptides, 187
  - 11.5.2 Serum Albumin Binding Small Molecules, 187
  - 11.5.3 Hydrophilic Polymers, 187
- 11.6 Conclusions, 188
- References, 189

## **12 Transferrin Fusion Protein Therapies: Acetylcholine Receptor-Transferrin Fusion Protein as a Model** **191**

*Dennis Keefe, Michael Heartlein, and Serene Josiah*

- 12.1 Disease Overview, 191
- 12.2 Fusion Protein SHG2210 Design, 192
- 12.3 Characterization of SHG2210, 193
  - 12.3.1 SHG2210 Binding and Internalization Studies in Cells, 193
  - 12.3.2 SHG2210 Anti-AchR Antibody Binding Studies, 193
  - 12.3.3 SHG2210: Anti-AchR Antibody Complex Binding and Internalization Studies in Cells, 194
  - 12.3.4 SHG2210 and SHG2210: Anti-AChR Antibody Complex Recycling Studies in Cells, 195
  - 12.3.5 Antigenic Modulation Studies, 195
  - 12.3.6 Summary of *In Vitro* Studies of SHG2210, 196
- 12.4 Applications and Indications, 196
- 12.5 Future Perspectives, 197
- 12.6 Conclusion, 198
- References, 198

## **13 Half-Life Extension Through O-Glycosylation** **201**

*Fuad Fares*

- 13.1 Introduction, 201
- 13.2 The Role of O-Linked Oligosaccharide Chains in Glycoprotein Function, 202
- 13.3 Designing Long-Acting Agonists of Glycoprotein Hormones, 203
  - 13.3.1 Construction of Chimeric Genes and Expression Vectors, 204
  - 13.3.2 Expression of Chimeric Genes, 204
  - 13.3.3 Bioactivity of Designed Long-Acting Glycoproteins, 205
    - 13.3.3.1 Follicle-Stimulating Hormone, 205
    - 13.3.3.2 Thyrotropin(TSH), 205

13.3.3.3	Erythropoietin (EPO), 205	
13.3.3.4	Human Growth Hormone (GH), 206	
13.4	Conclusions, 207	
	References, 207	
<b>14</b>	<b>ELP-Fusion Technology for Biopharmaceuticals</b>	<b>211</b>
	<i>Doreen M. Floss, Udo Conrad, Stefan Rose-John, and Jürgen Scheller</i>	
14.1	Introduction, 211	
14.2	ELP-based Protein Purification, 212	
14.3	ELPylated Proteins in Medicine and Nanobiotechnology, 215	
14.4	Molecular Pharming: a New Application for ELPylation, 217	
14.5	Challenges and Future Perspectives, 221	
14.6	Conclusion, 222	
	References, 222	
<b>15</b>	<b>Ligand-Receptor Fusion Dimers</b>	<b>227</b>
	<i>Sarbendra L. Pradhananga, Ian R. Wilkinson, Eric Ferrandis, Peter J. Artymiuk, Jon R. Sayers, and Richard J. Ross</i>	
15.1	Introduction, 227	
15.2	The GHLR-Fusions, 228	
15.3	Expression and Purification, 229	
15.4	Analysis of the LR-Fusions, 229	
15.4.1	Characterization, 229	
15.4.2	Biological Activity, 230	
15.4.3	Pharmacokinetics, 230	
15.4.4	Pharmacodynamics, 232	
15.4.5	Immunogenicity, 233	
15.4.6	Toxicology, 234	
15.5	LR-Fusions: The Next Generation in Hormone Treatment, 234	
15.6	Conclusion, 234	
	References, 234	
<b>16</b>	<b>Development of Latent Cytokine Fusion Proteins</b>	<b>237</b>
	<i>Lisa Mullen, Gill Adams, Rewas Fatah, David Gould, Anne Rigby, Michelle Sclanders, Apostolos Koutsokeras, Gayatri Mittal, Sandrine Vessillier, and Yuti Chernajovsky</i>	
16.1	Introduction, 237	
16.2	Description of Concept, 238	
16.3	Limitations of the Latent Cytokine Technology, 240	
16.4	Generation of Latent Cytokines, 242	
16.4.1	Molecular Design, 242	
16.4.2	Expression of LAP-Fusion Proteins, 243	
16.4.3	Purification of LAP-Fusion Proteins, 243	
16.5	Applications and Potential Clinical Indications, 244	
16.5.1	Multiple Sclerosis, 244	
16.5.1.1	Interferon $\beta$ , 244	
16.5.1.2	Interleukin 10, 245	
16.5.1.3	Erythropoietin, 245	
16.5.1.4	Transforming Growth Factor- $\beta$ , 245	
16.5.2	Rheumatoid Arthritis, 245	
16.5.2.1	Interferon $\beta$ , 245	
16.5.2.2	Interleukine 10, 246	
16.5.2.3	Interleukine 4, 246	

- 16.6 Alternatives/Variants of Approach, 246
- 16.7 Challenges (Production and Development), 247
- 16.8 Conclusions and Future Perspectives, 248
- Acknowledgments, 249
- References, 249

## **II B TOXIN: CYTOTOXIC FUSION PROTEINS 253**

### **17 Fusion Proteins with Toxic Activity 253**

*Stefan R. Schmidt*

- 17.1 Introduction, 253
- 17.2 Toxins, 254
  - 17.2.1 Microbial Toxins, 254
  - 17.2.2 Plant Toxins, 257
- 17.3 Immunocytokines, 258
  - 17.3.1 Interleukin 2 Fusion Proteins, 258
  - 17.3.2 GM-CSF Fusion Proteins, 258
  - 17.3.3 Other Leukocyte Attracting Cytokines and Chemokines, 258
- 17.4 Human Enzymes, 259
  - 17.4.1 Kinases, 259
  - 17.4.2 RNAses, 259
  - 17.4.3 Proteases, 260
  - 17.4.4 Antibody-Directed Enzyme Prodrug Therapy, 260
- 17.5 Apoptosis Induction, 261
  - 17.5.1 TNF Fusion Proteins, 261
  - 17.5.2 FasL Fusion Proteins, 262
  - 17.5.3 TRAIL Fusion Proteins, 262
  - 17.5.4 Intrinsic Apoptosis Inducing Fusion Proteins, 263
- 17.6 Fc-Based Toxicity, 263
  - 17.6.1 Antibody-Derived Cellular Cytotoxicity (ADCC), 263
  - 17.6.2 Antibody-Dependent Cell-Mediated Phagocytosis (ADCP), 264
  - 17.6.3 Complement-Dependent Cytotoxicity (CDC), 264
  - 17.6.4 Complement-Dependent Cell-Mediated Cytotoxicity (CDCC), 264
- 17.7 Peptide-Based Toxicity, 264
- 17.8 Conclusions and Future Perspectives, 265
- References, 265

### **18 Classic Immunotoxins with Plant or Microbial Toxins 271**

*Jung Hee Woo and Arthur Frankel*

- 18.1 Introduction, 271
- 18.2 Toxins Used in Immunotoxin Preparation, 272
  - 18.2.1 Diphtheria Toxin, 272
  - 18.2.2 Pseudomonas Exotoxin, 272
  - 18.2.3 Ricin, 274
  - 18.2.4 Gelonin and Saporin, 274
- 18.3 Immunotoxin Design and Synthesis, 274
- 18.4 Clinical Update of Immunotoxin Trials, 278
- 18.5 Challenges and Perspective of Classic Immunotoxins, 284
  - 18.5.1 Adverse Events, 284
  - 18.5.2 Immunogenicity, 285
- 18.6 Conclusions, 286
- References, 286

**19 Targeted and Untargeted Fusion Proteins: Current Approaches to Cancer Immunotherapy** **295**

*Leslie A. Khawli, Peisheng Hu, and Alan L. Epstein*

- 19.1 Introduction, 295
- 19.2 Immunotherapeutic Strategy for Cancer: Fusion Proteins, 296
- 19.3 Immunotherapeutic Applications of Antibody-Targeted and Untargeted Fc Fusion Proteins, 297
  - 19.3.1 Cytokine Fusion Proteins, 298
  - 19.3.2 Chemokine Fusion Proteins, 299
  - 19.3.3 Co-Stimulatory Fusion Proteins, 299
    - 19.3.3.1 B7.1 Fusion Proteins, 300
    - 19.3.3.2 CD137L Fusion Proteins, 301
    - 19.3.3.3 GITRL Fusion Proteins, 301
    - 19.3.3.4 OX40L Fusion Proteins, 302
  - 19.3.4 Enzyme Fusion Proteins, 303
  - 19.3.5 Vascular Targeting Fusion Proteins, 304
- 19.4 Combination Fusion Proteins Therapy, 305
  - 19.4.1 Cytokine Fusion Protein Combinations, 305
  - 19.4.2 Chemokine and Cytokine Synergy, 306
  - 19.4.3 Co-Stimulatory Fusion Protein Combinations, 306
- 19.5 Mechanism of Action: Immunoregulatory T-Cell ( $T_{reg}$ ) Depletion and Fusion Protein Combination Therapy, 306
  - 19.5.1 LEC Fusion Proteins in Combination with  $T_{reg}$  Depletion, 307
  - 19.5.2 CD137L and GITRL Fusion Proteins in Combination with  $T_{reg}$  Depletion, 308
- 19.6 Future Directions, 309
- 19.7 Conclusion, 309
- Acknowledgments, 310
- References, 310

**20 Development of Experimental Targeted Toxin Therapies for Malignant Glioma** **315**

*Nikolai G. Rainov and Volkmar Heidecke*

- 20.1 Introduction, 315
- 20.2 Targeted Toxins—General Considerations, 316
- 20.3 Delivery Mode and Pharmacokinetics of Targeted Toxins in the Brain, 316
- 20.4 Preclinical and Clinical Studies with Targeted Toxins, 318
  - 20.4.1 IL4-PE (NBI-3001), 318
  - 20.4.2 TP-38, 319
  - 20.4.3 IL13-PE38, 320
  - 20.4.4 TransMID-107 (Tf-CRM107), 322
- 20.5 Conclusions and Future Developments of Targeted Toxins, 324
- Disclosure, 325
- References, 325

**21 Immunokinases** **329**

*Stefan Barth, Stefan Gattenlöhner, and Mehmet Kemal Tur*

- 21.1 Introduction, 329
- 21.2 Protein Kinases, Apoptosis, and Cancer, 330
  - 21.2.1 General Properties of Protein Kinases, 330
  - 21.2.2 Death-Associated Protein Kinases (DAPKs), 330



21.2.3	The Role of DAPK1 and DAPK2 in Cancer, 331	
21.3	Therapeutic Strategies to Restore Missing Kinase Expression, 331	
21.3.1	Systemic Delivery of Demethylating Agents, 331	
21.3.2	Nontargeted Reactivation of Specific Protein Kinases, 332	
21.3.3	Targeted Reactivation of Specific Protein Kinases Using DAPK2-Based Immunokinases, 332	
21.4	Analysis of Immunokinase Efficacy, 333	
21.4.1	<i>In Vitro</i> Activity of Recombinant Immunokinase DAPK2'-CD30L, 333	
21.4.2	<i>In Vivo</i> Activity of Recombinant Immunokinase DAPK2'-CD30L, 333	
21.5	Outlook, 334	
	References, 334	
<b>22</b>	<b>ImmunoRNase Fusions</b>	<b>337</b>
	<i>Wojciech Ardelt</i>	
22.1	Introduction, 337	
22.1.1	Immunotoxins, 337	
22.1.2	Cytotoxic Activity of Ribonucleases, 337	
22.1.3	Ribonuclease Targeting to Cancer Cells, 338	
22.2	Development of ImmunoRNase Fusion Proteins as Biopharmaceuticals, 339	
22.2.1	Immuno-Fusion Proteins of Eosinophil-Derived Endotoxin or Angiogenin, 339	
22.2.2	Immuno-Fusion Proteins of Bovine Seminal Plasma RNase or Human Pancreatic RNase, 341	
22.2.3	Immuno-Fusion Proteins of Onconase <sup>®</sup> or Rana Pipiens Liver RNase, 342	
22.2.4	Barnase Immuno-Fusion Proteins, 343	
22.3	Aspects of ImmunoRNase Design and Production, 344	
22.3.1	Molecular Size and Valency, 344	
22.3.2	Interaction with Mammalian RNase Inhibitor, 344	
22.3.3	Cleavable ImmunoRNases, 345	
22.3.4	High-Level Production of ImmunoRNases, 345	
22.4	Alternatives, 346	
22.5	Conclusions and Future Perspectives, 347	
	References, 347	
<b>23</b>	<b>Antibody-Directed Enzyme Prodrug Therapy (ADEPT)</b>	<b>355</b>
	<i>Surinder K. Sharma</i>	
23.1	Introduction, 355	
23.2	The Components, 355	
23.2.1	The Target, 355	
23.2.2	The Antibody, 356	
23.2.3	The Enzyme, 356	
23.2.4	Abzymes or Catalytic Antibodies, 357	
23.2.5	Prodrugs, 357	
23.3	ADEPT Systems with Carboxypeptidase G2 (CPG2), 357	
23.3.1	System 1: Antibody-Enzyme Conjugates, 357	
23.3.1.1	Preclinical Studies, 357	
23.3.1.2	Removal of Enzyme Activity from Blood, 357	
23.3.1.3	First in Man ADEPT Study, 358	
23.3.1.4	Results of the First in Man ADEPT Study, 358	
23.3.1.5	Conclusions from the First in Man ADEPT Study, 358	

- 23.3.2 The Second Clinical Study of ADEPT, 358
  - 23.3.2.1 Conclusions from the Second Clinical Study of ADEPT, 359
- 23.3.3 The Third Clinical Study of ADEPT, 359
  - 23.3.3.1 Conclusions from the Third Clinical Study of ADEPT, 359
- 23.4 Fusion Proteins, 359
  - 23.4.1 The Fourth Clinical Study of ADEPT, 360
- 23.5 Immunogenicity, 360
- 23.6 Conclusions and Future Outlook, 361
- Acknowledgments, 361
- References, 361

**24 Tumor-Targeted Superantigens 365**

*Gunnar Hedlund, Göran Forsberg, Thore Nederman, Anette Sundstedt, Leif Dahlberg, Mikael Tiensuu, and Mats Nilsson*

- 24.1 Introduction: Tumor-Targeted Superantigens—A Unique Concept of Cancer Treatment, 365
- 24.2 Structure and Production of Tumor-Targeted Superantigens, 366
- 24.3 Tumor-Targeted Superantigens are Powerful Targeted Immune Activators and Useful for all Types of Malignancies, 367
- 24.4 Increasing the Therapeutic Window and Exposure by the Creation of a Novel TTS Fusion Protein with Minimal MHC Class II Affinity; Naptumomab Estafenatox, 370
- 24.5 Clinical Experience with TTS Therapeutic Fusion Proteins, 371
  - 24.5.1 Anatumomab Mafenatox, 371
  - 24.5.2 Naptumomab Estafenatox, 372
- 24.6 Combining TTS with Cytostatic and Immunomodulating Anticancer Drugs, 377
- 24.7 Conclusions, 379
- References, 379

**IIC TARGETING: FUSION PROTEINS ADDRESSING SPECIFIC CELLS, ORGANS, AND TISSUES 383**

**25 Fusion Proteins with a Targeting Function 383**

*Stefan R. Schmidt*

- 25.1 Introduction, 383
- 25.2 Targeting Organs, 383
  - 25.2.1 Brain, 383
  - 25.2.2 Liver, 385
  - 25.2.3 Lung, 386
  - 25.2.4 Bone, 387
  - 25.2.5 Thrombus Targeting, 387
- 25.3 Intracellular Delivery, 388
  - 25.3.1 Enzyme Replacement Therapy, 388
  - 25.3.2 Cell Penetrating Peptides, 389
  - 25.3.3 Antibody-Mediated Transduction, 390
  - 25.3.4 Endosome Escape and Cytosol Translocation, 390
- 25.4 Oral Delivery, 391
- 25.5 Conclusions and Future Perspectives, 392
- References, 393

- 26 Cell-Penetrating Peptide Fusion Proteins 397**  
*Andrés Muñoz-Alarcón, Henrik Helmfors, Kristin Karlsson, and Ülo Langel*
- 26.1 Introduction, 397
  - 26.2 Typical Applications and Indications, 397
  - 26.3 Technological Aspects, 399
    - 26.3.1 Creating CPP-Fusion Proteins, 399
    - 26.3.2 Recombinant Fusion Protein Expression Systems, 399
    - 26.3.3 Disulfide Bond, 400
    - 26.3.4 Biotin-Avidin Fusion Model, 401
    - 26.3.5 Expressed Protein Ligation, 401
    - 26.3.6 Purification, 401
    - 26.3.7 Purification Tag, 401
    - 26.3.8 Affinity Chromatography, 401
    - 26.3.9 Solid Phase Peptide Synthesis and High Performance Liquid Chromatography, 402
  - 26.4 Successes and Failures in Preclinical and Clinical Research, 402
    - 26.4.1 Preclinical Research, 402
    - 26.4.2 CPPs Used in Clinical Trials, 403
  - 26.5 Alternatives/Variants of This Approach, 405
  - 26.6 Conclusions and Future Perspectives, 405
  - Acknowledgments, 406
  - References, 406
- 27 Cell-Specific Targeting of Fusion Proteins through Heparin Binding 413**  
*Jiajing Wang, Zhenzhong Ma, and Jeffrey A. Loeb*
- 27.1 Why Target Heparan-Sulfate Proteoglycans with Fusion Proteins?, 413
  - 27.2 Heparan Sulfate Structure and Biosynthesis Create Diversity and a Template for Targeting Specificity, 415
  - 27.3 Tissue-Specific Expression of HSPGs and the Enzymes That Modify Them, 416
  - 27.4 Heparin-Binding Proteins and Growth Factors, 416
  - 27.5 Viruses Target Cells Through Heparin Binding, 417
  - 27.6 Dissecting Heparin-Binding Protein Domains for Tissue-Specific Targeting, 418
  - 27.7 Fusion Proteins Incorporating HBDs, 418
  - 27.8 The Neuregulin 1 Growth Factor Has a Unique and Highly Specific HBD, 419
  - 27.9 Using Neuregulin's HBD to Generate a Targeted Neuregulin Antagonist, 419
  - 27.10 Tissue Targeting and Therapeutic Efficacy of a Heparin-Targeted NRG1 Antagonist Fusion Protein, 420
  - 27.11 Conclusions and Future Perspectives, 423
  - References, 424
- 28 Bone-Targeted Alkaline Phosphatase 429**  
*José Luis Millán*
- 28.1 Detailed Description of the Concept, 429
  - 28.2 Technical Aspects, 430
  - 28.3 Applications and Indications, 432
  - 28.4 Preclinical and Clinical Research, 433

- 28.5 Alternatives/Variants of This Approach, 434
- 28.6 Challenges in Production and Development, 436
- 28.7 Conclusions and Future Perspectives, 436
- Acknowledgments, 437
- References, 437

**29 Targeting Interferon- $\alpha$  to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery** **441**

*Jessica Fioravanti, Jesús Prieto, and Pedro Berraondo*

- 29.1 Detailed Description of the Concept, 441
  - 29.1.1 Interferons, 441
  - 29.1.2 Stabilization of IFN- $\alpha$ , 442
  - 29.1.3 IFN- $\alpha$  Liver Targeting, 443
  - 29.1.4 Apolipoprotein A-I as a Scaffold for Peptide and Protein Delivery, 444
  - 29.1.5 Stabilization and Liver Targeting of IFN- $\alpha$  by Apolipoprotein A-I, 445
  - 29.1.6 Unexpected Properties of the Fusion Protein of Interferon- $\alpha$  and Apolipoprotein A-I, 446
- 29.2 Technological Aspects, 447
- 29.3 Typical Applications and Indications, 447
- 29.4 Alternatives and Variants of This Approach, 448
- 29.5 Conclusions and Future Perspectives, 448
- References, 448

**PART III BEYOND THE TRIPLE T-PARADIGM** **453**

**IIIA NOVEL CONCEPTS, NOVEL SCAFFOLDS** **455**

**30 Signal Converter Proteins** **455**

*Mark L. Tykocinski*

- 30.1 Introduction, 455
- 30.2 Historical Roots of Signal Conversion: Artificial Veto Cell Engineering and Protein Painting, 455
  - 30.2.1 Artificial Veto Cell Engineering, 456
  - 30.2.2 Protein Painting, 457
- 30.3 Trans Signal Converter Proteins, 458
- 30.4 Expanding Trans Signal Conversion Options: Redirecting Signals, 459
- 30.5 From Trans to Cis Signal Conversion: Driving Auto-Signaling, 460
- 30.6 Mechanistic Dividends of Chimerization, 461
- 30.7 Targeting Multiple Diseases with Individual Signal Converters, 462
- 30.8 Structural Constraints in SCP Design, 463
- 30.9 Coding SCP Functional Repertoires, 463
- 30.10 Expanding the Catalog of Inhibitory SCP, 464
- 30.11 Immune Activating SCP, 466
- 30.12 Experimental Tools for Screening SCP Candidates, 467
- 30.13 SCP Frontiers: Mining the Surface Protein Interactome, Rewiring Cellular Networks, 467
- References, 468

## **31 Soluble T-Cell Antigen Receptors**

475

*Peter R. Rhode*

- 31.1 Soluble T-cell Antigen Receptor (STAR) Fusion Technology and Utilities, 475
  - 31.1.1 Three Domains Single-Chain TCR (scTCR) Format and scTCR-Fusions, 476
  - 31.1.2 Mutagenesis and Multimerization for Improved Target Recognition, 477
- 31.2 Expression and Purification of Recombinant Star Fusion Proteins, 477
- 31.3 Clinical and Research Product Applications, 478
  - 31.3.1 Cancer Therapeutics, 478
  - 31.3.2 Viral Therapeutics, 479
  - 31.3.3 Diagnostic and Research Applications, 480
- 31.4 Preclinical Testing Using Star Fusion Proteins, 481
  - 31.4.1 Preclinical Efficacy, Pharmacokinetic, and Toxicity Studies, 481
  - 31.4.2 Antitumor Mechanism-of-Action Studies of ALT-801, 483
  - 31.4.3 Preclinical Efficacy Studies of Anticancer p53 Specific scTCRIgG1 Fusion Proteins, 485
  - 31.4.4 Evaluation of Combination p53-Specific STAR Fusion Protein and Chemotherapy Regimens in Tumor Efficacy Models, 486
- 31.5 Clinical Development of ALT-801, 487
  - 31.5.1 Monotherapy Clinical Study with ALT-801, 487
  - 31.5.2 ALT-801/Chemotherapy Phase II Studies, 487
- 31.6 Alternatives/Variants of This Approach, 488
  - 31.6.1 Development of Novel TCR-Targeted IL-15 Superagonist Fusions, 488
  - 31.6.2 Cell-Based Therapies, 489
- 31.7 Challenges, 489
- 31.8 Conclusions and Future Perspectives, 490
- Acknowledgments, 490
- References, 490

## **32 High-Affinity Monoclonal T-Cell Receptor (mTCR) Fusions**

495

*Nikolai M. Lissin, Namir J. Hassan, and Bent K. Jakobsen*

- 32.1 Introduction: The T Cell Receptor (TCR) as a Targeting Molecule, 495
- 32.2 Engineered High-Affinity Monoclonal TCRs (mTCR), 497
- 32.3 mTCR-Based Fusion Proteins for Therapeutic Applications, 500
- 32.4 Immune-Mobilizing Monoclonal TCRs Against Cancer (ImmTAC), 500
- 32.5 Conclusions and Future Perspectives, 503
- Acknowledgments, 504
- References, 504

## **33 Amediplase**

507

*Stefano Evangelista and Stefano Manzini*

- 33.1 Introduction, 507
- 33.2 Source, Physico-Chemical Properties and Formulation, 508
  - 33.2.1 Production Cell Line, 508
  - 33.2.2 Drug Substance, 508
  - 33.2.3 Drug Product, 509
- 33.3 Preclinical Studies, 510
  - 33.3.1 *In Vitro* Biological Properties, 510
    - 33.3.1.1 Plasminogen Activator Activity, 510
    - 33.3.1.2 *In Vitro* Thrombolytic Activity, 510

33.3.1.3	Fibrin Specificity, 510
33.3.1.4	Inhibition by Plasma Protease Inhibitors, 510
33.3.1.5	Binding to Fibrin, 510
33.3.1.6	Clot Penetration, 510
33.3.2	Pharmacodynamics: <i>In Vivo</i> Studies, 511
33.3.2.1	Thrombolytic Activity in Rabbits, 511
33.3.2.2	Thrombolytic and Haemorrhagic Effects in Rabbits, 511
33.3.2.3	Fibrinolytic Activity of Amediplase in Rats, 511
33.3.2.4	<i>In Vivo</i> Thrombolytic Activity of Amediplase in Dogs, 511
33.3.3	Pharmacokinetics, 511
33.3.3.1	Pharmacokinetics of Amediplase in Monkeys, 511
33.3.3.2	Pharmacokinetics of Amediplase in Rats, 511
33.3.3.3	The <i>In Vivo</i> Fate of Amediplase in Rats, 512
33.3.4	Toxicology, 512
33.4	Human Studies, 512
33.4.1	1K2 Study: A Phase I Single Ascending Dose Study, 512
33.4.2	2K2 Study: A Phase II, Multicenter, Open-Label, Dose-Finding, Pilot Study, 513
33.4.3	3K2 Study: A Double-Blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Two Doses of Amediplase, 514
33.5	Historical Comparison with Other Thrombolytics, 517
33.6	Conclusions and Future Perspectives, 517
	Acknowledgment, 517
	References, 517

## **34 Breaking New Therapeutic Grounds: Fusion Proteins of Darpins and Other Nonantibody Binding Proteins** **519**

*Hans Kaspar Binz*

34.1	Introduction, 519
34.2	Novel Scaffolds—Alternatives to Antibodies, 519
34.2.1	Success and Limitations of Antibodies, 519
34.2.2	Natural Binding Proteins, 520
34.2.3	Tailoring Nonantibody Binding Proteins, 521
34.2.4	DARPinS—Designed Ankyrin Repeat Proteins, 522
34.3	New Therapeutic Concepts with Nonantibody Binding Proteins, 523
34.3.1	Natural Fusion Protein Examples, 523
34.3.2	Fusion Proteins with Nonantibody Binding Proteins, 523
34.3.2.1	Bivalent and Bispecific Molecules, 523
34.3.2.2	Multispecific Constructs, 524
34.3.2.3	Critical Advantage of Multispecific Nonantibody Binding Proteins, 525
34.3.2.4	Combining Scaffolds with Other Effector Proteins, 525
34.4	Scaffold-Fusion Proteins Beyond Antibody Possibilities, 525
	Acknowledgments, 526
	References, 526

## **IIIB MULTIFUNCTIONAL ANTIBODIES** **529**

### **35 Resurgence of Bispecific Antibodies** **529**

*Patrick A. Baeuerle and Tobias Raum*

35.1	A Brief History of Bispecific Antibodies, 529
35.2	Asymmetric IgG-Like Bispecific Antibodies, 530

35.3	Symmetric IgG-Like Bispecific Antibodies,	531
35.4	IgG-Like Bispecific Antibodies with Fused Antibody Fragments,	533
35.5	Bispecific Constructs Based on the Fc $\gamma$ Fragment,	534
35.6	Bispecific Constructs Based on Fab Fragments,	535
35.7	Bispecific Constructs Based on Diabodies or Single-Chain Antibodies,	536
35.8	Bifunctional Fusions of Antibodies or Fragments with Other Proteins,	538
35.9	Bispecific Antibodies for Various Functions: How to Select the Right Format?,	539
	References,	541
<b>36</b>	<b>Novel Applications of Bispecific DART<sup>®</sup> Proteins</b>	<b>545</b>
	<i>Syd Johnson, Bhaswati Barat, Hua W. Li, Ralph F. Alderson, Paul A. Moore, and Ezio Bonvini</i>	
36.1	Introduction,	545
36.2	DART <sup>®</sup> Proteins,	546
36.3	Application of DART <sup>®</sup> to Cross-Link Inhibitory and Activating Receptors,	546
36.4	Application of Bispecific Antibodies in Oncology,	547
36.4.1	CD16-Based DART <sup>®</sup> Proteins,	547
36.4.2	CD3/TCR-Based DART <sup>®</sup> Proteins,	547
36.5	U-DART Concept for Screening DART <sup>®</sup> Candidate Targets and mAbs,	549
36.6	U-DART Concept for Applications in Autoimmune and Inflammatory Disease,	549
36.6.1	Inhibition of Basophil Degranulation,	553
36.7	Conclusions and Future Perspectives,	554
	References,	554
<b>37</b>	<b>Strand Exchange Engineered Domain (Seed): A Novel Platform Designed to Generate Mono and Multispecific Protein Therapeutics</b>	<b>557</b>
	<i>Alec W. Gross, Jessica P. Dawson, Marco Muda, Christie Kelton, Sean D. McKenna, and Björn Hock</i>	
37.1	Introduction,	557
37.2	Technical Aspects,	558
37.2.1	Workflow,	558
37.2.2	Therapeutic Formats,	560
37.2.3	Biophysical Properties,	561
37.2.4	Biological Properties,	562
37.3	Potential Therapeutic Applications,	562
37.4	Future Perspectives,	566
37.5	Conclusions,	567
	Acknowledgments,	567
	References,	567
<b>38</b>	<b>CovX-Bodies</b>	<b>571</b>
	<i>Abhijit Bhat, Olivier Laurent, and Rodney Lappe</i>	
38.1	The CovX-Body Concept,	571
38.2	Technological Aspects,	571
38.2.1	Scaffold Antibody,	571
38.2.2	Linker Design,	575
38.2.3	Choice of Payload,	577
38.2.4	Manufacture, Process, Characterization,	578

- 38.3 Applications of the CovX-Body Technology, 578
  - 38.3.1 CVX-060, a Selective Angiopoietin-2 Targeting CovX-Body, 578
  - 38.3.2 CVX-241, an Example of a Bispecific Antibody, 580
  - 38.3.3 CVX-343, Fusion of a Small Protein with CVX-2000, 581
- References, 581

**39 Modular Antibody Engineering: Antigen Binding Immunoglobulin Fc CH3 Domains as Building Blocks for Bispecific Antibodies (mAb<sup>2</sup>) 583**

*Maximilian Woisetschläger, Florian Rüker, Geert C. Mudde, Gordana Wozniak-Knopp, Anton Bauer, and Gottfried Himmeler*

- 39.1 Introduction, 583
- 39.2 Immunoglobulin Fc as a Scaffold, 583
- 39.3 Design of Libraries Based on the Human IgG1 CH3 Domain, 584
- 39.4 TNF- $\alpha$ -Binding Fcab: Selection and Characterization of Fcab TNF353-2, 585
- 39.5 Conclusions and Future Perspectives, 588
- Acknowledgments, 588
- References, 589

**40 Designer Fusion Modules for Building Multifunctional, Multivalent Antibodies, and Immunoconjugates: The Dock-and-Lock Method 591**

*Edmund A. Rossi, David M. Goldenberg, and Chien-Hsing Chang*

- 40.1 Introduction, 591
- 40.2 DDD/AD Modules Based on PKA and AKAP, 592
- 40.3 Advantages and Disadvantages of the DNL Method, 592
  - 40.3.1 Advantages of the DNL Method, 592
  - 40.3.2 Disadvantages of the DNL Method, 593
- 40.4 Fab-Based Modules, 593
- 40.5 IgG-AD2-Modules, 594
- 40.6 Hexavalent Antibodies, 595
- 40.7 More Antibody-Based-Modules and Multivalent Antibodies, 596
- 40.8 Nonantibody-Based DNL Modules, 597
- 40.9 IFN- $\alpha$ 2b-DDD2 Module and Immunocytokines, 597
- 40.10 Variations on the DNL Theme, 598
  - 40.10.1 Alternative Linker Modules, 598
  - 40.10.2 Alternative Covalent Stabilization, 598
- 40.11 Conclusions and Future Perspective, 599
- References, 599